¿Drs. Franco and Rohan bring together a timely and comprehensive set of reviews describing the biologic basis of carcinogenesis, issues related to measurement and interpretation of cancer precursors, site specific precancerous conditions, and control of cancer precursors ¿The book has several important strengths, most notably the wealth of current information on cancer precursors and related topics provided by an impressive cast of cancer researchers. ¿ it effectively provides specific and compelling reasons for studying cancer precursors, the most up-to-date and comprehensive collection of reviews on the topic, and a realistic picture of the complexities facing research of cancer precursors.¿ ¿American Journal of Epidemiology "In this book, Drs. Franco and Rohan have succeeded in preparing a comprehensive, timely, and critical review of the substantial progress that has been made in our understanding of cancer precursors. They have enlisted experts in the field who have contributed authoritative chapters to a wide variety of cancers with emphasis on the etiology and natural history, including the role of environmental and heritable factor that provoke normal cells to undergo malignant transformation. Epidemiologic data are linked whenever possible to molecular as well as clasical cellular pathology, providing a fuller understanding of the casual events and mechanisms that initiate the carcinogenic process." -From the Foreward by Joseph F. Fraumeni, Jr., M.D., M.S. Director, Division of Cancer Epidemiology and Genetics National Cancer Institute National Institutes of Health Rockville, MD This book provides an overview of the progress made in the last few years on the epidemiology, detection methods, and preventive stategies for cancer precursors. Contributors to the 25 chapters are among the world's most knowledgeable scientists in the areas of molecular pathology, epidemiology, and control of cancer precursors. Their reviews of the topic are accessible to a large professional base that includes basic cancer researchers, clinical oncologists, pathologists, molecular biologists, epidemiologists, nurses, health professionals working on policy implications, and graduate students in cancer-related fields. Divided into five sections, the book begins with brief overviews of the molecular basis of carcinogenesis and of the histological aspects of cancer precursors. Issues related to the measurement, interpretation, and the study of precursor lesions are addressed in Part II, including timely chapters on epidemiologic approaches to studying intermediate endpoints, the impact of measurement error, and methods of processing biological specimens for molecular epidemiology studies. The main section of the text is found in Part III, with chapters on cancer precursors at the most important anatomical sites at which solid tumors occur, including the lung, breast, colon, esophagus, and prostate. The site-specific reviews include discussions of the epidemiology of those lesions, and, where appropriate, aspects of their detection and prevention. The final sections of the book feature valuable overviews on screening and prevention strategies and the role of evidence-based medicine in judging the value of such strategies for national and international policy guidelines on cancer control.

The majority of cancers present at a relatively advanced stage in which invasion within the primary organ is well established and metastases to lymph and distant organs are either clinically apparent or present at the microscopic level. However, it is increasingly recognized that the natural history of cancer formation is a long and complex path taking many years to develop to a clinically apparent stage in most cases. Furthermore, for most solid tumours there is a pre-invasive or intraepithelial stage of disease. This affords the opportunity for early detection and prevention of invasive disease and hence a cure. However, with this advancing knowledge comes a whole plethora of questions which will be explored in this monograph. Firstly, we need to understand the global burden of pre-invasive disease and what the public health implications might be for wide-scale screening programmes. In the western world we already have experience of screening for cervical, breast, prostate and more recently colon cancer. As well as their potential benefits these programmes have financial and psychosocial implications which need to be carefully weighed. This is especially true since many pre-invasive lesions will not progress to cancer in a individual's lifetime. In addition, there are questions concerning whether screening reduces the cancer burden or in fact distorts the survival figures through lead-time bias. Secondly, at the level of epidemiology and molecular pathogenesis there are important questions regarding the aetiology of pre-invasive lesions; an understanding of which might lead to possible chemopreventive strategies. For example, it would be helpful to know the extent to which the likelihood of developing a pre-invasive lesion is influenced by lifestyle or genetic factors and how these factors influence the risk of progression to invasive disease. At the molecular level we need to understand the pathways and molecular mechanisms, both genetic and epigenetic, by which cells achieve the capacity to invade. Thirdly, in order make clinical progress we need biomarkers to identify and risk stratify individuals with pre-invasive lesions. These biomarkers might be applied to the serum as in Prostate Specific Antigen in prostate cancer or be applied to tissue samples, such as oestrogen receptor status in breast cancer. In order to utilize biomarkers in the context of a screening programme there are issue around the invasiveness of the test as well as its positive and negative predictive value. With advances in molecular imaging there is now the exciting possibility of incorporating a molecular tag to a non-invasive imaging modality. Fourthly, in order to justify screening early detection must be coupled to a treatment strategy. If the chemopreventive agent is very well tolerated, then as well as targeting high risk groups, one might consider treatment at the population level. Aspirin is one such drug which has been extensively assessed in the context of colon cancer chemoprevention trials. Trials of aspirin chemoprevention are now being applied to other cancers such as oesophageal adenocarcinoma and since many individuals take aspirin for .chemoprevention of cardiovascular disease the cancer incidence can be ascertained in these populations. In order to understand the more general issues raised from the discussions above it is useful to consider disease specific examples. Our understanding of pre-invasive disease varies according to the organ site and there are lessons to be learned from these experiences. For example, there is now the prospect of a vaccine for cervical cancer with important questions about how this might be applied to the high incidence areas of the developing world. On the other hand, ductal carcinoma in situ is currently treated by mastectomy which is more radical than the treatment received by many women with invasive disease. Oesophageal adenocarcinoma, which is my own area of expertise is interesting because of the rapid rise in incidence in the western world and the clinically accessible pre-invasive lesion called Barrett's oesophagus. However, most cases of Barrett's oesophagus remain undiagnosed and it is not yet clear how to effectively diagnose, monitor and treat this condition without recourse to mass endoscopy with substantial cost implications. In conclusion, in an era in which preventive medicine is a major concern for consumers, health-policy makers and politicians pre-invasive disease is likely to become a major part of cancer medicine.

Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. They discuss the means by which these immune functions may be protected or restored in order to more effectively support the process of tumor rejection in situ. Cutting-edge techniques are outlined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

The possibility of treating cancer, a disease frequently defined by
genetic defects, by introducing genes that target these very
alterations has generated tremendous enthusiasm. This enthusiasm,
however, has been tempered by an increasing number of obstacles to
successful therapy, including vector systems that do not reach systemic
metastases, therapeutic genes with redundant mechanisms allowing for
cellular resistance, and toxicities in clinical trials that result in
premature closure. The three comprehensive sections of this volume
present currently available cancer gene therapy techniques, with
specific attention to these trouble spots. Part I describes the various
aspects of gene delivery including vehicles, or vectors, and their
respective characteristics and production methods. In Part II, the
contributors discuss strategies and targets for the treatment of
cancer, including methods for cell-death therapies, correction of
underlying genetic defects at the molecular level, and activation of
the immune system or tumor microenvironment. The contributors provide a
succinct framework for understanding the basic underlying oncogenic
changes, which encourages the development of vectors engineered to
exploit these gene mutations through selective spread of the vector in
tumor cells with the specific changes. Finally, in Part III, experts in
clinical gene therapy trials discuss the difficulties inherent in
bringing gene therapy treatment for cancer to the clinic, and principal
investigators present gene therapy approaches in the clinical testing
stage and the results that have reached the stage ofclinical
testing.of these trials.

With the coming of the new millennium we are witnessing a revolution in our understanding of cancer genetics. These are very exciting times. Today we have at our disposal the technology to diagnose abnormalities in our cancer genes and the means to correct the deficit and very soon we will have the complete sequence of the human genome. With the use of gene chip technology the way doctors will be able to assess patients will change completely. Today we can diagnose abnormalities in ten thousand genes and within a short period of time we will be able to screen through our genome and discover potential abnormalities in our proto-oncogenes, tumour suppressor genes, differentiating genes, apoptotic genes and pro-inflammatory genes. In this book various authors have highlighted specific genes that could be expressed, overexpressed, neutralised or h- nessed to achieve cancer control. The problem of transferring the therapeutic gene into the cancer cell has been partly addressed with major developments in the field of naked plasmid DNA, adenovirus, retrovirus and adeno-associated viruses. However, further improvements are yet to be made to achieve significant gene transfer. Gene expression, in particular specificity of gene transfer, is obviously an important issue and one which is highlighted in this book by the use of specific promoter.

This book is a simple guide to the diagnosis, investigation, and treatment of all gynaecological cancers. It discusses the management of patients with gynaecological malignancies; considers the principles of chemotherapy, radiotherapy, and surgery; explains when and why each modality is used in treatment; covers the pathology of gynaecological cancer; discusses treatment of the advanced disease; and includes a chapter on the role of palliative care. The multidisciplinary approach reflects the cooperative practice in combined clinics.

This book represents an essential reference manual for all of the well-characterized leukemia-lymphoma cell lines currently available. It provides the most important facts, using the succinct and user-friendly format that has made the FactsBooks so popular with scientists and clinical researchers. Introductory chapters provide background and perspective for culturing malignant hematopoietic (blood forming) cell lines. These chapters are followed by over 400 comprehensive individual entries. Each cell line entry highlights essential clinical, immunological, genetic, and functional features and includes a comprehensive listing of references.
Key Features
* the full spectrum of malignant cell lines from all hematopoietic cell lineages
* sister cell lines and relevant subclones
* clinical data: patient, diagnosis, treatment status, and specimen source
* authentication of derivation and availability
* immunophenotype
* cytogenetic karyotype
* translocations and fusion genes
* receptor gene rearrangements and genetic alterations
* cell cultures aspects: establishment, medium, doubling time, growth
* cytochemical profile
* cytokine production and response to cytokines
* proto-oncogene and transcription factor expression/alteration
* functional features: differentiation induction, heterotransplantability
* special unique features
* key references

This volume provides a biological and pharmacological background for regional cancer therapy, strategies and techniques for regional therapies, and specific indications and results for different tumor entities. Clinical trial concepts and detailed treatment protocols are also presented. This book is essential reading for researchers and clinicians engaged in seeking advanced therapeutic options for cancer patients worldwide.

This volume, Biological and Hormonal Therapies of Cancer, which is part of the series Cancer Treatment and Research, presents selected new information concerning biologic and hormonal therapy of cancer. We have attempted to provide the reader with topics of major interest in a timely fashion. There is renewed interest in biologic therapy of cancer. Two chapters review the role of interferon in the hematologic malignancies and in solid tumors. Vaccine therapies have come to the forefront of cancer therapy re cently, and two chapters approach different strategies of vaccine therapies; one reviews the cellular vaccine therapies and another the anti-idiotype ap proach. The hormonal therapy chapters focus on current uses of endocrine therapy in endometrial, breast, and prostate cancer. In addition, hormonal strategies for the prevention of breast cancer and endometrial cancer, including excit ing information relating to phytochemicals, are presented. The effects of tamoxifen on endometrium is a topic of major interest and is discussed in detail. Finally, there is a chapter on estrogen receptor expression and regula tion in human breast cancer. These chapters are all written by experts in the field and contain timely and relevant information of interest to laboratory and clinical scientists and practitioners alike. Biologic and endocrine therapies represent major areas of cancer research interest. The advent of newer biologic therapies, including new antibody targeted treatments, and the use of biologics as tumor modulators to enhance the effects of other treatment regimens is an exploding avenue of research."

This textbook is unique in that it is the first European text for nurses practicing beyond the novice level in cancer nursing. Previously European cancer nurses have had to rely on North American texts, which are not always culturally transferable. The book presents a synthesis of important issues, which underpin the practice of advanced cancer nursing and are vital to experiencedpractitioners in moving cancer nursing forward. The central concerns of the book reflect the emerging roles of the advanced specialist practitioner and include advanced practice, education, management and research. The text is written by recognised cancernursing experts from throughout Europe who collectively are involved in shaping the future of cancer nursing across the continent.Unique collection of authors from Europe who are recognised for their respective roles in shaping the future of cancer nursing Key text for those engaging in postgraduate studies on practicing at an advanced level.Explores the different domains of advanced practice in cancer nursing which are necessary to move the specialty forward Unique European text for cancer nurses wishing to develop expert knowledgeBased on current research data Produced under the auspices of EONS

The field of microRNA biology is really emerging in the last couple of years. Several investigators highlighted the importance of miRNAs in cancer. Although there is so much literature on microRNAs exist, a comprehensive book is still not available. Thus this book will be a great use to the scientists in the field of cancer biology. In addition, this book will be a good source of information for undergraduate, graduate students who want to develop their research careers in cancer biology.

Hematopathology: Genomic Mechanisms of Neoplastic Diseases will keep physicians abreast of the rapid and complex changes in genomic medicine, as exemplified by the molecular pathology of hematologic malignancies. This timely volume will update physicians on the complexities of genomic lesions, as well as offer an integrated framework encompassing molecular diagnosis, the new WHO classification of hematologic neoplasms with focus on molecular pathology, prognostic value of molecular tests, and molecular monitoring of response to gene-targeted therapy. As such, it will be of great value to hematologists, oncologists, pathologists, internal medicine and pediatric specialists, as well as bioscientific staff and laboratorians in private hospitals and academic institutions.

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here once again, outstanding and original reviews are presented.
Key Features
* New Paradigms for the Treatment of Cancer: The Role of Anti-aiogenesis Agents
* The Hepatocyte Growth Factor/Met Pathway in Development, Tumorigenesis, and B-Cell Differentiation
* Clinical Targets for Anti-metastasis Therapy
* Animal Models of Melanoma: Recent Advances and Future Prospects
* The Indispensable Role of Microenvironment in the Natural History of Low-Grade B-Cell Neoplasms
* Epstein-Barr Virus Latency: LMP2, a Regulator or Means for Epstein-Barr Birus
* Biochemistry and Pathological Importance of Mucin-Associated Antigens in Gastrointenstinal Neoplasia
* Studies on Polyomavirus Persistence and Polyomavirus-Induced Tumor Development in Relation to the Immune System

My training started in 1971, when I joined the First Department of Medicine of Chiba University, as Dr. Kunio Okuda became chair ofthe department. To acquire training ingeneralpathology, Iapplied for the Intern MatchingProgram and started as aninternin the DepartmentofPathologyofYale University, in 1973.While Iwas achiefresident, Ispent 10months in Dr. GeraldKlatskin'sofficestudyingthe com plete set of his famous liver biopsy samples (the Klatskin Collection). In 1976, I movedtoJohnWesleyHospital, where therewasagroup from the USC (University ofSouthern California) Liver Unit, to obtain further pathology training under the guidanceofDr. Robert L. Peters. Those experiences have given me ample opportu nity to see the differences between the United States and Japan. Ofcourse, 28 years ago in downtown Los Angeles there were enormous num bers ofpatients suffering from typical alcoholic liver diseases. Now in Japan, in contrast, we have an enormous number ofpatients suffering from hepatocellular carcinoma (HCC), due in particular to hepatitis C viral infection. Last year, in the DepartmentofGastroenterology at the University ofTokyo, we had approximately 500 admissions due to HCC. Thus, we have an urgent need to prevent the develop ment ofHCC and to provide better treatment for such patients through a basic un derstanding ofvirology, clinical features, and treatment modalities. The first single-topic conference on "TherapyofViral Hepatitis and Prevention ofHepatocellular Carcinoma" was organized by the Japan Society ofHepatology (Kiwamu Okita, Director General) and was held November 14-15,2002, near Mt. Fuji. Thisbook, which is asummaryofthe meeting, helps toupdate relevantinforma tion on this vital topic. June 28, 2003 Masao Ornata, M.D."

Protein kinase CK2 (formerly casein kinase II or 2) is known to play a critical role in the control of cell growth and cell death and is thus intimately involved in the development of cancer. More specifically, CK2 has been found to be elevated in all cancers examined. While CK2 levels are known to be high in proliferating normal cells, CK2 has also been found to be a potent suppressor of apoptosis and is a link to the cancer cell phenotype, which is characterized by deregulation of both cell proliferation and cell death. Indeed, it would appear that CK2 impacts many of the hallmarks of cancer and it has now gained considerable attention as a potential target for cancer therapy. Protein Kinase CK2 and Cellular Function in Normal and Disease States increases knowledge of the role of CK2 in the development of cellular dysfunction and emphasizes that this protein may serve as a target of drug development for improved cancer therapy. In addition, it is a handy tool that provides cancer researchers, graduate students, and all scientists involved in CK2 research with one main source for the latest advances in CK2 research.

Of the two disciplines in parallel development for two decades, tumor immunology and transplantation immunology, the latter has thrived and has led to some of the most critical discoveries in immunobiology. The former continues to thwart both scientists and clinicians alike.
The goal of immunologists in modern day research is to develop a simple and effective means to manipulate cancer "in vivo, " possibly encompassing several venues: identifying a phenotypic marker and the use of either active or passive immunization; include the use of passive reagents carrying "warheads" to selectively destroy cancer cells; or altering the basic process of cell survival.
This excellent multidiscipline-authored volume presents a theme which has not been well described before. The papers include both basic and clinical science and range from sophisticated molecular biology to little more than phenomenology (e.g. the increased association of cancer in some autoimmune diseases and increased presentation of autoimmune phenomena in malignant condition). This, however, is state-of-the-art.
This collection of themes will be of use not only to bench scientists, but also to clinicians who treat patients. The book represents progress at the cutting edge of this discipline, and points the way to further developments in the "black box" of immunology.

This volume details basic principles of experimental and computational methods for the study of microRNAs in cancer research and, therefore, provides a firm grounding for those who wish to develop further applications. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, MicroRNA and Cancer: Methods and Protocols, Second Edition aims to ensure successful results in the further study of this vital field

This vital collection provides a unique set of techniques to explore the clinical, pathological, and research aspects of the management of patients with esophageal adenocarcinoma. Beginning with an introduction to the basic features of esophageal adenocarcinoma, the book continues with clinical protocols for the management of the cancer, pathological methods for management of the patients and research, as well as protocols for molecular research, which could aid researchers in furthering our understanding of pathogenesis as well as in identifying new targets for the treatment and prevention of adenocarcinoma. Written for the highly successful Methods in Molecular Biology series, chapters include introductions on their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and tips on troubleshooting and avoiding known pitfalls. Comprehensive and authoritative, Esophageal Adenocarcinoma: Methods and Protocols is a valuable guide to stimulate specialists from various disciplines in their continuing research into esophageal adenocarcinoma and translating that research into improving the management of this cancer of rising importance.

Gene expression studies have revealed diagnostic profiles and upregulation of specific pathways in many solid tumors. The explosion of new information in gene expression profiling could potentially lead to the development of tailored treatments in many solid tumors. In addition many studies are ongoing to validate these signatures also in predicting response to hormonal, chemotherapeutic and targeted agents in breast cancer as well as in other tumors. Diagnostic, Prognostic and Therapeutic Value of Gene Signatures provides readers a useful and comprehensive resource about the range of applications of microarray technology in oncological diseases. Topics covered include gene signatures and soft tissue sarcomas, prognostic relevance of breast cancer signatures, gene expression profiling of colorectal cancer and liver metastasis, gene signatures in GISTs, CNVs and gene expression profiles in pancreatic cancer, and gene signatures in head/neck, lung and gastric tumors. Diagnostic, Prognostic and Therapeutic Value of Gene Signatures will be of great value to residents and fellows, physicians, pathologists and medical oncologists.

Diverse molecular, cellular, and environmental events must all come together to allow the successful formation of secondary cancers, metastases. The second edition of Metastasis Research Protocols, brings together the most up to date versions of the seminal techniques that were presented in the first edition and also includes new techniques that have recently been shown to be important in illuminating the processes underlying this important area of biology. Presented by top scientists, the collection includes a wide spectrum of articles encompassing important key methods and to introduce new methods which are making an impact in the area of metastasis research. Volume 1 includes key cellular and molecular techniques relevant to the exploration of cancer cells and tissues, the focus is on the tools that have been shown to be helpful in unravelling the molecular processes important in cancer metastasis. Written in the highly successful Methods in Molecular Biology (TM) series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Metastasis Research Protocols, Second Edition seeks to aid scientists in the further study of new methods in the area of metastasis research.

In recent decades, cytopathology has assumed an increasing role in the primary diagnosis of mass lesions owing to its ability to deliver rapid, non-invasive, and timely information. This book provides a comprehensive overview of the role of cytology at various body sites. The diagnostic details covered are abbreviated in comparison with those in pathology texts. Instead, a more clinical approach is taken, with the focus on the advantages and limitations of techniques and the key features of entities that are important to clinicians. Pathological-clinical correlation is highlighted throughout the book, ensuring that it will be highly relevant for clinicians. In particular, physicians who deal with oncology patients will find it to be a rich source of guidance on how to use and understand cytopathology in the diagnosis and exclusion of malignancy.

This volume represents a collection of contributions from the 6th International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Related Diseases held in Boston from September 12-15, 1999. The mission of this meeting was to bring together senior and junior investigators to both announce and examine their recent advancements in cutting-edge research on the roles and actions of lipid mediators and their impact in human physiology and disease pathogenesis. The meeting focused on new concepts in these areas of interest to both clinicians and researchers. The program included several outstanding plenary lectures and presentations by leading experts in the fields of cancer and inflammation. In addition, the Boston meeting presented three Young Investigator awards, one in each of the major focus areas. The meeting was exciting and proved to be very memorable. The program was developed with an emphasis on recent advances in molecular and of lipid mediators relevant in cellular mechanisims involved in the formation and actions inflammation and cancer. Plenary lectures were presented by Prof. Bengt Sammuelsson (Karolinska Institute, Stockholm; 1982 Nobel Laureate in Physiology or Medicine) and Prof. E. 1. Corey (Harvard University; 1990 Nobel Laureate in Chemistry). Both of these plenary lectures were held on Day 1, which set an exciting tone for this meeting. Immediately following these plenary lectures, three simultaneous breakout sessions were held, one of inflammation, a second on cancer and synthesis of novel inhibitors, and a third on enzymes-lipoxygenases/cyclooxygenases and inhibitors.

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. CLL has a highly varied clinical course. While advances in CLL therapy are noted, many patients still succumb to this illness. Like most progress in medicine, solid advances in the diagnosis, prognosis and treatment of CLL are rooted in an in-depth understanding of the basic and translational biology of CLL. In this book, CLL experts have contributed state-of-the-art summaries of various important aspects of CLL biology and have discussed the translational implication of such findings. This book, which is directed at physicians and researchers alike, aims to educate broadly and deeply. Intentionally, the many aspects and nuances of CLL clinical care that can only really be appreciated through direct patient care are not covered here, but instead, the book presents basic aspects of CLL that underlie many of the contemporary decisions that are made in CLL research and clinical settings.
We hope that this book will critically inform the community and stimulate interest in CLL, which will ultimately translate into better CLL research, prognostication and therapy, with the end goal of providing a better outlook for patients afflicted with this common leukemia."